EPS · actual vs est
Revenue · actual vs est
Summary
Generated 2025-03-05
Management highlights
- Quarter four marked the first full quarter after selling the physical security business, allowing focus on specialty IoT solutions. Proceeds from the sale strengthened financial position. - Kim Macaulay joined as head of commercial organization to drive sales expansion and business development. - RFID production transition from Singapore to Thailand is progressing well; 75% of volume transitioned to Thailand in December, with remaining customers to be transferred by end of quarter two. - New product development pipeline includes various projects like smart labels for consumables, rugged BLE devices, etc. - Partnership with Novanta announced, combining Novanta's reader modules and APIs with Identiv's inlay portfolio for medical device solutions.
Segment performance
Fourth quarter 2024 revenue was $6.7 million. Fiscal year 2024 revenue was $26.6 million, a decrease of $16.8 million compared to the prior year period, primarily due to lower sales of BLE transponder and mobile products. Q4 2024 GAAP gross margin was negative 14.9% and non-GAAP gross margin was negative 5.2%. Fiscal year 2024 GAAP gross margin was 1.3% and non-GAAP gross margin was 8%. The decline in gross margins was largely due to the production transition to Thailand.
Guidance
- Q1 2025 net revenue expected in the range of $4.8 million to $5.1 million. - Target non-GAAP gross margin of 26% to 28% once full production is in Thailand. - Focus on organic growth and M&A-driven growth within the PAT framework.
Risks
- Potential delays in the production transition from Singapore to Thailand. - Impact of legacy low-margin customers on margins. - Tariff risks related to manufacturing in Thailand (though currently assessed as manageable).
Q&A highlights
Q: Expand on when first revenues from Novanta partnership and gross margin targets for partnerships.
A: Partnership with Novanta is technology and business development focused, not directly on revenue. For commercial partnerships, there are revenue and gross margin targets, with medical partnerships typically having higher margins.
Q: When will the grocery store device opportunity impact and ASP details.
A: Hopes to have early volumes by end of this year or early next year. It's a higher price point than typical portfolio products, iterative development due to harsh environment.
Q: Quantify pull-in order in Q4 and cadence of gross margin throughout 2025.
A: Pull-in order was largely responsible for Q4 beat by ~$600,000. Cadence of gross margin beyond one quarter not formally guided, but directionally in ballpark.
Q: EBITDA breakeven timeline and tariff risk.
A: No formal EBITDA breakeven timeline. Assessed as in good spot for tariffs related to manufacturing in Thailand.
Key numbers
Reported versus consensus
Earnings calendar feed
| Metric | Reported | Consensus | Delta | Prior year |
|---|---|---|---|---|
| EPS | $-0.19 | $-0.25 | +24.0% | $-0.08 |
| Revenue | $6.7M | $6.1M | +9.5% | $29.0M |
Transcript
March 5, 2025Full transcript unavailable for redistribution
The structured summary above covers the available call sections. Full transcript text is not included on this page.
Continue exploring
Prior quarters
This page presents the stored structured earnings-call summary and deterministic earnings calendar values. How this is generated. For informational purposes only; not investment advice.